Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

TGTX has rallied to a fresh 52-week high amid anticipation of its Q3 results, with traders also debating whether the move reflects BRIUMVI growth and momentum or speculative buyout and short-covering activity. The earnings date remains unconfirmed, and the company has not confirmed acquisition rumors.

Albemarle is under pressure amid falling lithium spot and futures prices, with traders concerned about the impact on earnings and guidance. The community is split between expecting more downside and viewing the selloff as a buying opportunity, citing longer-term EV and energy-storage demand.

CVS is drawing attention over weaker 2027 Medicare Advantage star ratings for Aetna, which traders worry could reduce bonus revenue and pressure margins. The reaction is mixed: some see a meaningful setback relative to Humanas improved ratings, while others question whether the impact is already reflected in the stock.

FUBO is drawing attention for a sharp, low-volume slide toward recent lows, with many traders saying the decline lacks a clear news catalyst and voicing concerns about the business, dilution and the post-merger outlook. The discussion is split between bearish calls for further losses and investors waiting for upcoming earnings and the new CEOs strategy update to show whether Disney integration can improve the outlook.

Updated NSCLC trial results and Iovances move toward biomarker-selected patient groups are driving attention: the overall response rate held near prior levels, while a retrospective subgroup showed a stronger signal, but durability and regulatory implications remain uncertain. Traders are split between viewing the subgroup strategy as promising and seeing a narrower, later lung opportunity, with frustration over the datas presentation and the sharp selloff ahead of earnings.

Whirlpools weak Q1 results, reduced full-year outlook and dividend suspension are driving attention, with management citing recession-level appliance demand and the Iran war. Traders are sharply divided between fears of further financial distress and hopes that the selloff has created an oversold buying opportunity.

Cloroxs sharply weaker fiscal outlook and ongoing sales and margin pressures have fueled a steep selloff, with traders focused on the earnings-driven decline and fresh lows. The community is split between viewing the lower price and high dividend as a long-term value opportunity and warning that weak execution and a potentially strained payout could mean further downside.

Inovios FDA approval of a competing RRP treatment has put pressure on Precigens PAPZIMEOS, prompting debate over whether the new entrant will erode its sales. Some traders see a threat from the rivals surgery-sparing treatment, while others point to PAPZIMEOS first-mover and commercialization lead and the uncertainty surrounding Inovios accelerated approval and launch.

CELH is drawing attention for its recent strength as traders discuss money rotating out of tech and look ahead to Q3 earnings. Sentiment is split between hopes for improving sales, Alani Nu growth and stronger recent Nielsen data, and concerns about weakness in the core Celsius brand, margins and management execution.

Dutch Bros steep selloff and repeated 52-week lows are driving discussion, with traders weighing whether the decline is an oversold buying opportunity or a repricing of its still-high valuation amid concerns about consumer spending, growth, and competition. Some point to store expansion and continued business growth as reasons for optimism, while others expect further downside ahead of earnings.